BRIEF published on 06/12/2025 at 22:10, 1 year 3 months ago DBV Technologies participation in the EAACI 2025 congress DBV Technologies Food Allergies Epicutaneous Immunotherapy Viaskin® Peanut EAACI 2025
PRESS RELEASE published on 06/12/2025 at 22:05, 1 year 3 months ago DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies to participate in the upcoming EAACI Congress 2025, presenting data on peanut patch and cow's milk allergy diagnosis. Symposium on epicutaneous immunotherapy and clinical relationships DBV Technologies Food Allergies Epicutaneous Immunotherapy Peanut Allergy EAACI Congress
BRIEF published on 06/11/2025 at 22:35, 1 year 3 months ago DBV Technologies: Unanimous adoption of resolutions at the 2025 General Meeting General Assembly DBV Technologies Viaskin Food Allergies Resolutions Adopted
PRESS RELEASE published on 06/11/2025 at 22:30, 1 year 3 months ago DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting DBV Technologies announces the voting results of its 2025 Combined General Meeting where shareholders approved all proposed resolutions. Visit their website for more details Shareholders Voting Results Resolutions DBV Technologies 2025 Combined General Meeting
BRIEF published on 06/04/2025 at 22:37, 1 year 3 months ago DBV Technologies: Update of voting rights and shares as of May 30, 2025 Share Capital Voting Rights Actions DBV Technologies NYSE Euronext Paris
PRESS RELEASE published on 06/04/2025 at 22:32, 1 year 3 months ago Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025 Press release on total number of voting rights and shares of the Company as of May 30, 2025, for NYSE Euronext Paris with ISIN Code FR 0010417345 Voting Rights Shares Financial Disclosure ISIN Code NYSE Euronext Paris
BRIEF published on 06/03/2025 at 22:35, 1 year 3 months ago DBV Technologies Files Addendum to 2024 Registration Document AMF Corporate Governance Registration Document DBV Technologies CEO Compensation
PRESS RELEASE published on 06/03/2025 at 22:30, 1 year 3 months ago DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies files addendum to 2024 Universal Registration Document with updates on CEO compensation. Company focuses on food allergy treatments with Viaskin technology DBV Technologies Food Allergies CEO Compensation Addendum Viaskin Technology
BRIEF published on 05/15/2025 at 22:35, 1 year 3 months ago DBV Technologies to hold its Combined General Meeting on June 11, 2025 Shareholders Biopharmaceuticals DBV Technologies General Meeting 2025 Retransmission
PRESS RELEASE published on 05/15/2025 at 22:30, 1 year 3 months ago Combined General Meeting of June 11, 2025 DBV Technologies to hold Combined General Meeting on June 11, 2025 in Châtillon, France. Shareholders can request meeting documents until June 06, 2025. Webcast available on company's website Shareholders Webcast Combined General Meeting DBV Technologies Meeting Documents
Published on 09/12/2026 at 02:35, 1 day 20 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 2 days ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 2 days 1 hour ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days 6 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 1 day 5 hours ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 15 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 2 days ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 2 days ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 2 days 3 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 16 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 3 days 3 hours ago Availability of the 2026 Interim Financial Report
